CaliPharms, Inc.
KGET
$0.00
$0.000.00%
| 09/30/2014 | 06/30/2014 | ||||
|---|---|---|---|---|---|
| Revenue | 81.82% | 68.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 81.82% | 68.37% | |||
| Cost of Revenue | 32.68% | 104.84% | |||
| Gross Profit | 58.66% | -237.74% | |||
| SG&A Expenses | 38.33% | -50.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.98% | -39.85% | |||
| Operating Income | -28.74% | 46.17% | |||
| Income Before Tax | -218.95% | -67.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -218.95% | -67.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -218.95% | -67.35% | |||
| EBIT | -28.74% | 46.17% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -200.00% | -33.33% | |||
| Normalized Basic EPS | -300.00% | 0.00% | |||
| EPS Diluted | -200.00% | -33.33% | |||
| Normalized Diluted EPS | -300.00% | 0.00% | |||
| Average Basic Shares Outstanding | 9.24% | 1.02% | |||
| Average Diluted Shares Outstanding | 9.24% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
